Two new phase 2 frontline 3F8 trials open at Memorial Sloan-Kettering in NY

High-dose 3F8 trials for high-risk neuroblastoma in first remission

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

The purpose of these studies is to see if high-dose 3F8 and GM-CSF is better than standard dose 3F8 in treating neuroblastoma in first remission.

The study with children who have not undergone transplant will accrue 58 patients, and the study that includes children who have undergone transplant as part of frontline therapy will accrue 43 patients.

Both studies include Accutane (13-cis-retinoic acid) and use high-dose (80 mg/m2/day) 3F8 for the first 4 cycles, and standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.

13-cis-retinoic acid is started after cycle 2 in both studies.